Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Ulcerative Colitis

In brief

The primary objective of this study is to evaluate the effect of abrilumab on induction of remission in adults with moderate to severe ulcerative colitis after 8 weeks of treatment as assessed by a total Mayo Score ≤ 2 points, with no individual subscore \> 1 point.

Key facts

Study ID

NCT01694485

Run by

Amgen

People needed

359

Starts

2012-11-16

Expected to finish

2018-04-10

Last updated by the study team

2019-06-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of ulcerative colitis (UC) established ≥ 3 months before baseline by clinical and endoscopic evidence and corroborated by a histopathology report.
• Moderate to severe active UC as defined by a total Mayo score of 6 to 12 with a centrally read rectosigmoidoscopy score ≥2 prior to baseline
• Inadequate response to, loss of response to, or intolerance to at least one of the following treatments:
• Immunomodulators
• Anti-TNF agents
• Corticosteroids (non-US sites only).
• Neurological exam free of clinically significant, unexplained signs or symptoms during screening and no clinically significant change prior to randomization

You may not qualify if…

• Disease limited to the rectum (ie, within 10 cm of the anal verge)
• Toxic megacolon
• Crohn's Disease
• History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for UC
• Planned bowel surgery within 24 weeks from baseline
• Stool positive for C. Difficile toxin at screening
• History of gastrointestinal surgery within 8 weeks of baseline
• Primary Sclerosing Cholangitis
• Any uncontrolled or clinically significant systemic disease
• Condition or disease that, in the opinion of the investigator would pose a risk to subject safety or interfere with study evaluation, procedures or completion.
• Known to have tested positive for hepatitis B virus surface antigen, hepatitis C virus antibody or human immunodeficiency virus (HIV)
• Underlying condition that predisposes subject to infections (eg, uncontrolled diabetes; history of splenectomy)
• Known history of drug or alcohol abuse within 1 year of screening
• Malignancy (other than resected cutaneous basal or cutaneous squamous cell carcinoma, or treated in situ cervical cancer considered cured) within 5 years of screening visit (if a malignancy occurred > 5 years ago, subject is eligible with documentation of disease free state since treatment)
• Immunosuppressive therapy with either cyclosporine A, tacrolimus, or mycophenolate mofetil, within 1 month prior to baseline
• Prior exposure to anti tumor necrosis factor (TNF) agents, within 2 months, or 5 times the respective elimination half life (whichever is longer) prior to baseline
• Any prior exposure to vedolizumab, rituximab, efalizumab, natalizumab
• Use of topical (rectal) aminosalicylic acid (eg, mesalamine) or topical (rectal) steroids within 2 weeks prior to baseline
• Use of intravenous or intramuscular corticosteroids within 2 weeks prior to screening and during screening
• Previously treated with AMG 181
• Received any type of live attenuated vaccine < 1 month prior to baseline or is planning to receive any such live attenuated vaccine over the course of the study
• Treatment of infection with intravenous (within 30 days of baseline) or oral (within 14 days prior to baseline) antibiotics, antivirals, or antifungals
• Abnormal laboratory results at screening
• Any other laboratory abnormality, which, in the opinion of the investigator, will prevent the subject from completing the study or will interfere with the interpretation of the study results
• Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s)

Where it is running

• Research Site — Dothan, Alabama, United States
• Research Site — Mobile, Alabama, United States
• Research Site — Scottsdale, Arizona, United States
• Research Site — La Jolla, California, United States
• Research Site — Torrance, California, United States
• Research Site — Lone Tree, Colorado, United States
• Research Site — Jacksonville, Florida, United States
• Research Site — Miami, Florida, United States
• Research Site — Naples, Florida, United States
• Research Site — Atlanta, Georgia, United States
• Research Site — Arlington Heights, Illinois, United States
• Research Site — Urbana, Illinois, United States
• Research Site — Hammond, Louisiana, United States
• Research Site — Chesterfield, Michigan, United States
• Research Site — Rochester, Minnesota, United States
• Research Site — Great Neck, New York, United States
• Research Site — New York, New York, United States
• Research Site — Charlotte, North Carolina, United States
• Research Site — Greenville, North Carolina, United States
• Research Site — Mentor, Ohio, United States
• Research Site — Germantown, Tennessee, United States
• Research Site — San Antonio, Texas, United States
• Research Site — Seattle, Washington, United States
• Research Site — Seattle, Washington, United States
• Research Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.